Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases
About this trial
This is an interventional treatment trial for Anemia (Iron-Loading)
Eligibility Criteria
Inclusion Criteria: Patients meeting any of the following health conditions and eligible for Chronic PIH Treatment Non- transfusion-dependent patients with iron-loading anemias Transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine Iron-loaded, transfusion-dependent patients Ages: 18-75 years old Exclusion Criteria: People who are not eligible for chronic PIH therapy and not meet the medical conditions listed in the Inclusion criteria Ages: 17 years old or younger or 76 years old or older
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Chronic therapy of PIH according to medical condition
Placebo
Half of overall participants will get one of the following doses according to their medical condition: Reducing the body iron burden to near-normal levels in non- transfusion-dependent patients with iron-loading anemias (requires chelate- induced iron excretion of at least 0.10 to 0.20 mg Fe/kg/day); Maintaining near-normal body iron stores in transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine (requires chelate-induced iron excretion of at least 0.25 to 0.40 mg Fe/kg/day); Reducing the body iron burden to near-normal levels in iron-loaded, transfusion-dependent patients (requires chelate-induced iron excretion greater than 0.40 mg Fe/kg/day).
Half of the participants will receive a Placebo: Non-transfusion-dependent patients Transfusion-dependent patients Iron-loaded, transfusion-dependent patients